|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2009-12-16
|
|
pubmed:abstractText |
Moxifloxacin-based triple therapy has been suggested as an alternative first line therapy to clarithromycin-based triple therapy for Helicobacter pylori infection.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1349-7235
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2069-76
|
|
pubmed:meshHeading |
pubmed-meshheading:20009394-Aza Compounds,
pubmed-meshheading:20009394-Clarithromycin,
pubmed-meshheading:20009394-Drug Therapy, Combination,
pubmed-meshheading:20009394-Female,
pubmed-meshheading:20009394-Helicobacter Infections,
pubmed-meshheading:20009394-Helicobacter pylori,
pubmed-meshheading:20009394-Humans,
pubmed-meshheading:20009394-Male,
pubmed-meshheading:20009394-Metronidazole,
pubmed-meshheading:20009394-Odds Ratio,
pubmed-meshheading:20009394-Proton Pump Inhibitors,
pubmed-meshheading:20009394-Quinolines,
pubmed-meshheading:20009394-Randomized Controlled Trials as Topic,
pubmed-meshheading:20009394-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials.
|
|
pubmed:affiliation |
Evidence-Based Medicine Center of Lanzhou University, Lanzhou, China.
|
|
pubmed:publicationType |
Journal Article,
Meta-Analysis
|
